Clinical trials: Relapsing Multiple Sclerosis (RMS)
Multiple Sclerosis
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
Multiple sclerosis (MS) is an immune-mediated disease characterized primarily by inflammatory demyelinating lesions in the central nervous system (CNS), with the white matter being predominantly affected.
- Trial name
- NCT07353216
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Relapsing Forms of Multiple Sclerosis
A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
In this study, researchers will learn more about the study drugs diroximel fumarate (DRF) and dimethyl fumarate (DMF) in children with MS who may be experiencing relapses.
- Trial name
- VOYAGE (NCT07483632)
- Testing
- Diroximel Fumarate, Dimethyl Fumarate, Fingolimod
- Volunteers
- 185 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
- Conditions
- Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis
- Trial name
- NCT07006805
- Testing
- CABA-201
- Sponsor
- Cabaletta Bio
Relapsing Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
- Trial name
- ENABLE (NCT06433752)
- Testing
- No Intervention
- Where
- 111 sites in United States, Puerto Rico and 1 more
- Volunteers
- 2,000 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05156281
- Testing
- Remibrutinib, Teriflunomide
- Where
- 223 sites in United States, Argentina and 25 more
- Volunteers
- 1,007 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
The purpose of this study is to test the RebiSmart™ for ease of use multiple domains related to subject's acceptability and satisfaction reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in subjects…
- Trial name
- Performs (NCT01036165)
- Testing
- RebiSmart™
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Myasthenia Gravis
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or…
- Trial name
- NCT06220201
- Testing
- CC-97540, Fludarabine, Cyclophosphamide
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 120 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Sclerosis
A Long-term Extension of Study GNC-401
This Phase II study is a monocenter, long-term extension study of study GNC-401 and will start after individual completion of Week 48 of the GNC-401 study. At entry, all patients will receive active treatment with temelimab.
- Trial name
- NCT05049161
- Testing
- Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- GeNeuro Innovation SAS
Relapsing Multiple Sclerosis
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to…
- Trial name
- NCT07220252
- Testing
- Ublituximab, Fingolimod
- Where
- 3 sites in Poland
- Volunteers
- 240 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
This non-interventional study aims to observe the effect of early versus late Ofatumumab treatment in RMS patients in a real-world setting in Austria over an observational period of 24 months.
- Trial name
- KRONOS (NCT05776888)
- Testing
- Ofatumumab
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
Significant data from placebo-controlled clinical trials have demonstrated the efficacy of Rebif in relapsing remitting multiple sclerosis (RRMS) with reduction in relapse rate, delay in disability progression, and reduction in…
- Trial name
- COMPARE (NCT01141751)
- Volunteers
- 334 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
- Trial name
- NCT02576717
- Testing
- RPC1063
- Where
- 175 sites in United States, Belarus and 24 more
- Volunteers
- 2,494 people
- Sponsor
- Celgene
Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS.
- Trial name
- FENhance 2 (NCT04586023)
- Testing
- Fenebrutinib, Teriflunomide
- Where
- 106 sites in United States, Austria and 15 more
- Volunteers
- 751 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis (RMS)
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without…
- Trial name
- NCT02921035
- Testing
- Rebif (Interferon beta-1a)
- Where
- 41 sites in Algeria, Argentina and 11 more
- Volunteers
- 594 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, MS
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
This is a multi-center, two-arm non-comparative, observational, 96 week Phase IV study to evaluate treatment adherence when using RebiSmart™ for self-injection of Rebif® in subjects with relapsing multiple sclerosis (RMS).
- Trial name
- MEASURE (NCT01128075)
- Testing
- RebiSmart™
- Where
- Canada
- Volunteers
- 198 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple…
- Trial name
- NCT06846281
- Testing
- Remibrutinib oral treatment, Ocrelizumab
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
- Trial name
- NCT07211633
- Testing
- Ublituximab
- Where
- 48 sites in Bosnia and Herzegovina, Bulgaria and 7 more
- Volunteers
- 360 people
- Sponsor
- TG Therapeutics, Inc.
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
- Trial name
- NCT05147220
- Testing
- Remibrutinib, Teriflunomide
- Where
- 200 sites in United States, Argentina and 32 more
- Volunteers
- 1,000 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)
In the proposed study, investigators will assess the safety and feasibility of cycles of a fasting mimicking diet (FMD) and its effect on Multiple Sclerosis Quality of Life (MSQOL) in relapsing MS (RMS) patients treated with…
- Trial name
- FMDMS (NCT06515782)
- Testing
- Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Southern California
Multiple Sclerosis, Relapsing
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with…
- Trial name
- NCT04377555
- Testing
- Ocrelizumab
- Where
- 28 sites in United States, Kenya and 1 more
- Volunteers
- 179 people
- Sponsor
- Genentech, Inc.